Literature DB >> 16261409

High incidence of 4153delA BRCA1 gene mutations in Lithuanian breast- and breast-ovarian cancer families.

Jacek Gronwald1, Pavel Elsakov, Bohdan Górski, Jan Lubiński.   

Abstract

BRCA1 and BRCA2 gene mutations confer a high lifetime risk to breast and ovarian cancers. We have screened cancer patients from 13 families with at least three breast and/or ovarian cancers from Lithuania for 5382insC, C61G and 4153delA BRCA1 gene mutations. One of three mutations was found in 9 of the 13 studied families (69%). 4153delA was the most frequently detected and accounted for 56% of all identified mutation. 5382insC and C61G accounted for 33% and 11% of found mutations, respectively. Significantly higher, than in other populations, incidence of 4153delA indicates that this may be founder BRCA1 mutation characteristic for Lithuanians. Our analysis shows that testing of 4153delA, 5382insC, C61G BRCA1 mutations should be extremely effective and inexpensive tool in testing Lithuanian population aimed to identify individuals with high risk of breast and ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16261409     DOI: 10.1007/s10549-005-5150-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  The 4154delA mutation carriers in the BRCA1 gene share a common ancestry.

Authors:  Silvija Ozolina; Olga Sinicka; Eriks Jankevics; Inna Inashkina; Jan Lubinski; Bohdan Gorski; Jacek Gronwald; Tatyana Nasedkina; Olga Fedorova; Ludmila Lyubchenko; Laima Tihomirova
Journal:  Fam Cancer       Date:  2008-12-09       Impact factor: 2.375

2.  BRCA1 4153delA founder mutation in Russian ovarian cancer patients.

Authors:  Nadezhda Yu Krylova; Oksana S Lobeiko; Anna P Sokolenko; Aglaya G Iyevleva; Maxim E Rozanov; Natalia V Mitiushkina; Madina M Gergova; Tatiana V Porhanova; Adel F Urmancheyeva; Sergey Ya Maximov; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2006-09-15       Impact factor: 2.857

3.  Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.

Authors:  Pavel Elsakov; Juozas Kurtinaitis; Valerij Ostapenko
Journal:  Fam Cancer       Date:  2007-05-23       Impact factor: 2.375

4.  Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.

Authors:  Grigorijs Plakhins; Arvids Irmejs; Andris Gardovskis; Signe Subatniece; Santa Rozite; Marianna Bitina; Guntars Keire; Gunta Purkalne; Uldis Teibe; Genadijs Trofimovics; Edvins Miklasevics; Janis Gardovskis
Journal:  BMC Med Genet       Date:  2011-10-27       Impact factor: 2.103

5.  Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.

Authors:  Anna P Sokolenko; Maxim E Rozanov; Natalia V Mitiushkina; Natalia Yu Sherina; Aglaya G Iyevleva; Elena V Chekmariova; Konstantin G Buslov; Evgeny S Shilov; Alexandr V Togo; Elena M Bit-Sava; Dmitry A Voskresenskiy; Oleg L Chagunava; Peter Devilee; Cees Cornelisse; Vladimir F Semiglazov; Evgeny N Imyanitov
Journal:  Fam Cancer       Date:  2007-02-28       Impact factor: 2.446

6.  Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.

Authors:  Oubaida ElBiad; Abdelilah Laraqui; Fatima El Boukhrissi; Chaimaa Mounjid; Maryame Lamsisi; Tahar Bajjou; Hicham Elannaz; Amine Idriss Lahlou; Jaouad Kouach; Khadija Benchekroune; Mohammed Oukabli; Hafsa Chahdi; Moulay Mustapha Ennaji; Rachid Tanz; Yassir Sbitti; Mohammed Ichou; Khalid Ennibi; Bouabid Badaoui; Yassine Sekhsokh
Journal:  BMC Cancer       Date:  2022-02-25       Impact factor: 4.430

7.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

8.  BRCA1 founder mutations compared to ovarian cancer in Belarus.

Authors:  Alena Savanevich; Oleg Oszurek; Jan Lubiński; Cezary Cybulski; Tadeusz Dębniak; Steven A Narod; Jacek Gronwald
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.